CING

Cingulate Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$4.49

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %25.3 / %30

Non-compliant assets / Total market cap %0 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Website

Analysis (Turkish): CING Hissesi Caiz mi, Helal mi? Cingulate Inc. Katılım Analizi